Skip to main content

Research Repository

Advanced Search

All Outputs (3)

Fevipiprant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy (2016)
Journal Article
Sykes, D. A., Bradley, M. E., Riddy, D. M., Willard, E., Reilly, J., Miah, A., …Charlton, S. J. (2016). Fevipiprant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy. Molecular Pharmacology, 89(5), 593-605. https://doi.org/10.1124/mol.115.101832

Here we describe the pharmacologic properties of a series of clinically relevant chemoattractant receptor-homologous molecules expressed on T-helper type 2 (CRTh2) receptor antagonists, including fevipiprant (NVP-QAW039 or QAW039), which is currently... Read More about Fevipiprant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy.

Long receptor residence time of C26 contributes to super agonist activity at the human ?2 adrenoceptor (2016)
Journal Article
Rosethorne, E. M., Bradley, M. E., Gherbi, K., Sykes, D. A., Sattikar, A., Wright, J. D., …Charlton, S. J. (2016). Long receptor residence time of C26 contributes to super agonist activity at the human β2 adrenoceptor. Molecular Pharmacology, 89(4), 467-475. https://doi.org/10.1124/mol.115.101253

Super agonists produce greater functional responses than endogenous agonists in the same assay, and their unique pharmacology is the subject of increasing interest and debate. We propose that receptor residence time and the duration of receptor signa... Read More about Long receptor residence time of C26 contributes to super agonist activity at the human ?2 adrenoceptor.

The role of kinetic context in apparent biased agonism at GPCRs (2016)
Journal Article
Javitch, J. A., Klein Herenbrink, C., Sykes, D. A., Donthamsetti, P., Canals, M., Coudrat, T., …Lane, J. R. (2016). The role of kinetic context in apparent biased agonism at GPCRs. Nature Communications, 7, Article 10842. https://doi.org/10.1038/ncomms10842

Biased agonism describes the ability of ligands to stabilize different conformations of a GPCR linked to distinct functional outcomes and offers the prospect of designing pathway-specific drugs that avoid on-target side effects. This mechanism is usu... Read More about The role of kinetic context in apparent biased agonism at GPCRs.